Literature DB >> 11979513

Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder.

Murat Kuloglu1, Bilal Ustundag, Murad Atmaca, Halit Canatan, A Ertan Tezcan, Nadire Cinkilinc.   

Abstract

Recent data from several reports indicate that free radicals are involved in aetiopathogenesis of many human pathologies including neuropsychiatric disorders such as schizophrenia, bipolar disorder etc. In the present study, we aimed at determining and evaluating levels of malondialdehyde (MDA), a product of lipid peroxidation, and antioxidant enzyme superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) activity levels in patients diagnosed with schizophrenia (n = 25) and bipolar disorder (n = 23). The control group was composed of 20 healthy subjects. There was a significant increase in MDA levels of patients with schizophrenia and bipolar disorder compared with controls. SOD and GSH-Px activity levels were significantly higher in the schizophrenic group compared with controls. SOD activity levels in bipolar the group were significantly higher than controls whereas there were no significant changes in GSH-Px activity levels in the bipolar group and controls. Significant differences between lipid peroxidation product and antioxidant enzyme (SOD and GSH-Px) activity levels in schizophrenic and bipolar disorder patients compared with controls leads us to believe that these differences are related to the heterogenities in aetiologies of these disorders. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11979513     DOI: 10.1002/cbf.940

Source DB:  PubMed          Journal:  Cell Biochem Funct        ISSN: 0263-6484            Impact factor:   3.685


  66 in total

Review 1.  Antioxidants as antidepressants: fact or fiction?

Authors:  Giovanni Scapagnini; Sergio Davinelli; Filippo Drago; Antonino De Lorenzo; Giovannangelo Oriani
Journal:  CNS Drugs       Date:  2012-06-01       Impact factor: 5.749

Review 2.  New therapeutic targets for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Nancy DiazGranados; Lobna Ibrahim; David Latov; Cristina Wheeler-Castillo; Jacqueline Baumann; Ioline D Henter; Carlos A Zarate
Journal:  ScientificWorldJournal       Date:  2010-04-13

3.  Oxidative stress in early stage Bipolar Disorder and the association with response to lithium.

Authors:  Rafael T de Sousa; Carlos A Zarate; Marcus V Zanetti; Alana C Costa; Leda L Talib; Wagner F Gattaz; Rodrigo Machado-Vieira
Journal:  J Psychiatr Res       Date:  2013-12-06       Impact factor: 4.791

Review 4.  Oxidative stress in schizophrenia: an integrated approach.

Authors:  Byron K Y Bitanihirwe; Tsung-Ung W Woo
Journal:  Neurosci Biobehav Rev       Date:  2010-10-23       Impact factor: 8.989

5.  3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder.

Authors:  Ana Cristina Andreazza; Flavio Kapczinski; Marcia Kauer-Sant'Anna; Julio C Walz; David J Bond; Carlos A Gonçalves; L Trevor Young; Lakshmi N Yatham
Journal:  J Psychiatry Neurosci       Date:  2009-07       Impact factor: 6.186

Review 6.  TRPC channels and their implication in neurological diseases.

Authors:  Senthil Selvaraj; Yuyang Sun; Brij B Singh
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-03       Impact factor: 4.388

7.  Effect of chronic N-acetyl cysteine administration on oxidative status in the presence and absence of induced oxidative stress in rat striatum.

Authors:  Brian H Harvey; Charise Joubert; Jan L du Preez; Michael Berk
Journal:  Neurochem Res       Date:  2007-08-31       Impact factor: 3.996

8.  Lipid peroxidation markers in children with anxiety disorders and their diagnostic implications.

Authors:  Mehmet Fatih Ceylan; Esra Guney; Murat Alisik; Merve Ergin; Gulser Senses Dinc; Zeynep Goker; Sevda Eker; Murat Kizilgun; Ozcan Erel
Journal:  Redox Rep       Date:  2014-01-13       Impact factor: 4.412

Review 9.  Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Lobna A Ibrahim; Nancy Diaz-Granados; Carlos A Zarate
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

10.  Metallomic profiling and linkage map analysis of early Parkinson's disease: a new insight to aluminum marker for the possible diagnosis.

Authors:  Shiek S S J Ahmed; Winkins Santosh
Journal:  PLoS One       Date:  2010-06-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.